Weight management · Phase 3
SYNCHRONIZE-1: survodutide weight management
What was tested?
Survodutide versus placebo alongside lifestyle intervention in adults with overweight or obesity, excluding diabetes. ↗
Registered primary question: Percentage weight change and the proportion losing at least 5% of baseline weight at week 76. ↗
What the reviewed report found
Journal year 2026 · Article summary reviewed 2026-09-15
The treatment-regimen analysis reported mean weight changes of −12.2% and −13.0% in the active groups versus −5.4% with placebo. Gastrointestinal events occurred in 80.9% and 89.7% of active groups versus 47.9% with placebo.↗
Keep in context: The paper describes 725 participants and the registry lists 726 enrolled. Its treatment-regimen estimates include treatment discontinuation and other specified intercurrent events; they should not be mixed with efficacy estimates from a different analysis. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 726 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Quadruple
- Design
- Parallel
- Eligible ages
- 18 Years; maximum not specified
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2026-03-12; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
SYNCHRONIZE-1: phase 3 obesity study
- Design in the report
- A blinded randomized placebo-controlled trial assessed percentage weight change and at least 5% weight reduction at 76 weeks, under NCT06066515.↗
- Participants in the report
- The report describes 725 adults with obesity or overweight with a related complication, excluding diabetes.↗
- Limitations
- The analysis includes treatment discontinuation and other specified intercurrent events. Weight reduction does not itself establish fewer cardiovascular events or other long-term complications. No deaths were reported.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight ↗
Protocol identifier: 1404-0038. Sponsor: Boehringer Ingelheim.
Retrieved 2026-09-20; SHA-256 d69eb3440ca5ae0a808fae8cbb19c76f1d76e52c9f902e34bd039afaeaeb0035.
PMID 42253238
Survodutide Once Weekly for the Treatment of Adults with Obesity. ↗
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 42253238. SHA-256 adc8edd8b150d99a3641ddbc74c59db6916cf35d9d6246838aaff2cc195ae1cb.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 af8146d991ea6927b0e5f817c6ba5c66af5c5b9047dcafda697686a950bddc74.